Navigation Links
Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
Date:9/23/2008

SAN DIEGO, Sept. 23 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that Douglas B. Muchmore, MD, has joined the company as Vice President, Endocrinology Clinical Development.

"I am thrilled to welcome an individual of Dr. Muchmore's high caliber and achievement to the Halozyme leadership team. He is a widely respected endocrinologist for his talent and experience in drug development, clinical medicine, and regulatory interaction in academic, research, and corporate settings. Doug's addition to Halozyme will immediately add value to the advancement of our insulin and bisphosphonate programs," said Jonathan Lim, MD, President and CEO of Halozyme Therapeutics. "His decision to join Halozyme further validates the quality of our research programs, the promise of our technology, and the exciting potential of our ongoing product development efforts. Doug Muchmore exemplifies Halozyme's steadfast commitment to attract, develop, and retain top talent with extensive experience in each of our therapeutic disciplines and in all functional areas of the company."

Dr. Muchmore has more than 30 years of professional experience in clinical drug development, clinical research trial design and implementation, and the practice of endocrinology. His experience spans all stages of clinical development in the field of endocrinology, where he has direct experience with diabetes and osteoporosis indications. Prior to joining Halozyme, Dr. Muchmore served as Medical Fellow II on the Insulins and Devices Team and a member of the Diabetes Platform Team at Eli Lilly and Co. He acted as the key scientific develope
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference
3. Halozyme Therapeutics Reports 2007 Third Quarter Financial Results
4. Halozyme Therapeutics Amends Stockholder Rights Plan
5. Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
7. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
8. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
9. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
10. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
11. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email: